ATE450526T1 - Als antagonisten von histamin h3 geeignete piperidinderivate - Google Patents

Als antagonisten von histamin h3 geeignete piperidinderivate

Info

Publication number
ATE450526T1
ATE450526T1 AT06773528T AT06773528T ATE450526T1 AT E450526 T1 ATE450526 T1 AT E450526T1 AT 06773528 T AT06773528 T AT 06773528T AT 06773528 T AT06773528 T AT 06773528T AT E450526 T1 ATE450526 T1 AT E450526T1
Authority
AT
Austria
Prior art keywords
histamine
antagonists
piperidine derivatives
derivatives suitable
piperidine
Prior art date
Application number
AT06773528T
Other languages
English (en)
Inventor
Robert Aslanian
Michael Berlin
Christopher Boyce
Jianhua Chao
Lera Ruiz Manuel De
Pietro Mangiaracina
Kevin Mccormick
Mwangi Mutahi
Stuart Rosenblum
Neng-Yang Shih
Daniel Solomon
Wing Tom
Henry Vaccaro
Junying Zheng
Xiaohong Zhu
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE450526T1 publication Critical patent/ATE450526T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials
AT06773528T 2005-06-20 2006-06-19 Als antagonisten von histamin h3 geeignete piperidinderivate ATE450526T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69211005P 2005-06-20 2005-06-20
PCT/US2006/023800 WO2007001975A1 (en) 2005-06-20 2006-06-19 Piperidine derivatives useful as histamine h3 antagonists

Publications (1)

Publication Number Publication Date
ATE450526T1 true ATE450526T1 (de) 2009-12-15

Family

ID=36968725

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06773528T ATE450526T1 (de) 2005-06-20 2006-06-19 Als antagonisten von histamin h3 geeignete piperidinderivate

Country Status (17)

Country Link
US (2) US7635705B2 (de)
EP (1) EP1902046B1 (de)
JP (1) JP2008546784A (de)
KR (1) KR20080021082A (de)
CN (1) CN101243072A (de)
AR (1) AR054787A1 (de)
AT (1) ATE450526T1 (de)
AU (1) AU2006262441A1 (de)
CA (1) CA2610959A1 (de)
DE (1) DE602006010870D1 (de)
ES (1) ES2337727T3 (de)
HK (1) HK1121737A1 (de)
IL (1) IL187984A0 (de)
MX (1) MX2008000115A (de)
TW (1) TW200738676A (de)
WO (1) WO2007001975A1 (de)
ZA (1) ZA200710968B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
CA2634235A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
EP2079695A2 (de) * 2006-10-20 2009-07-22 Arete Therapeutics, INC. Phenylharnstoff-verbindungen als lösliche epoxid-hydrolase-hemmer
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
CA2675450A1 (en) * 2007-01-29 2008-08-07 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
CL2008000594A1 (es) * 2007-03-02 2008-09-05 Schering Corp Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades.
WO2008112022A1 (en) * 2007-03-13 2008-09-18 Arete Therapeutics, Inc. 4 -pi peridinylurea compounds as soluble epoxide hydrolase inhibitors
KR101506156B1 (ko) 2007-04-23 2015-03-26 얀센 파마슈티카 엔.브이. 속해리성 도파민 2 수용체 길항제로서의 티아(디아)졸
ES2393818T3 (es) 2007-04-23 2012-12-28 Janssen Pharmaceutica, N.V. Derivados de tipo 4-alcoxipiridazina como antagonistas de los receptores 2 de la dopamina de disociación rápida
EP2141994A4 (de) * 2007-04-26 2011-05-18 Avalon Pharmaceuticals Mehrringverbindungen und ihre verwendungen
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
JP5417439B2 (ja) 2008-07-03 2014-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ５−ｈｔ６受容体アンタゴニストとしての置換された６−（１−ピペラジニル）−ピリダジン類
EP2318388A2 (de) 2008-07-23 2011-05-11 Schering Corporation Tricyclische spirocyclusderivate und verfahren zu deren verwendung
CN102171189B (zh) 2008-07-31 2013-11-20 詹森药业有限公司 作为快速解离多巴胺2受体拮抗剂的哌嗪-1-基-三氟甲基取代的吡啶
JP5642661B2 (ja) * 2009-03-05 2014-12-17 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
US8337835B2 (en) * 2009-04-10 2012-12-25 Washington University Use of an endogenous ligand for peroxisome proliferator activated receptor alpha to treat liver disorders
EP2527340B1 (de) * 2010-01-22 2016-08-17 Taiho Pharmaceutical Co., Ltd. Piperazinverbindung mit pgds-inhibierender wirkung
CA2801074A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
SG191884A1 (en) * 2011-01-07 2013-08-30 Targacept Inc Nicotinic receptor non-competitive antagonists
US8865641B2 (en) * 2011-06-16 2014-10-21 The Feinstein Institute For Medical Research Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
US8658787B2 (en) 2011-09-16 2014-02-25 Galectin Therapeutics Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CN102657868A (zh) * 2012-05-30 2012-09-12 中国药科大学 5-羟色胺2受体拮抗剂或转运体抑制剂治疗脂肪肝或高脂血症
US9763974B2 (en) 2012-06-06 2017-09-19 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN109082465A (zh) * 2018-08-20 2018-12-25 苏州市广济医院 奥氮平诱导糖代谢紊乱相关疾病的分子标志物及其用途
SG11202110742TA (en) 2019-04-02 2021-10-28 Aligos Therapeutics Inc Compounds targeting prmt5
WO2021187605A1 (ja) * 2020-03-19 2021-09-23 田辺三菱製薬株式会社 含窒素複素環αシアノカルボニル化合物

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US661145A (en) * 1900-08-06 1900-11-06 Otto Hausmann Attachment for bicycles.
US856473A (en) * 1906-05-21 1907-06-11 Daniel E Krause Drilling-machine.
US4983567A (en) * 1987-03-16 1991-01-08 Biomeasure, Inc. Immunomodulators and methods of making same
US4983597A (en) 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5561227A (en) * 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
DE69222532T2 (de) * 1991-07-23 1998-02-26 Schering Corp Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
ATE205475T1 (de) * 1993-07-09 2001-09-15 Schering Corp Verfahren zur herstellung von azetidinonen
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5618707A (en) * 1996-01-04 1997-04-08 Schering Corporation Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
WO1997016424A1 (en) 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5886171A (en) * 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
KR20000029975A (ko) 1996-08-16 2000-05-25 둘락 노먼 씨. 히스타민수용체길항제의배합물을사용한상부기도알레르기반응의치료
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US5869479A (en) * 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
US6133001A (en) * 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
WO1999065867A1 (en) * 1998-06-17 1999-12-23 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
US5919672A (en) * 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
US6207822B1 (en) * 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
AU4343500A (en) * 1999-04-16 2000-11-02 Schering Corporation Use of azetidinone compounds
CN1210274C (zh) * 2000-02-11 2005-07-13 沃泰克斯药物股份有限公司 哌嗪和哌啶衍生物
US20020045686A1 (en) * 2000-08-24 2002-04-18 The Yokohama Rubber Co., Ltd Rubber composition having improved wet skid resistance and rolling resistance
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
IL156550A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
MXPA03005019A (es) * 2000-12-21 2003-09-25 Avantis Pharma Deutschland Gmb Derivados de difenilazetidinonas, metodo para su produccion farmacos que contienen estos compuestos y su uso.
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
MY131890A (en) * 2001-03-13 2007-09-28 Schering Corp Piperidine compounds
DE60206365T2 (de) * 2001-03-28 2006-07-06 Schering Corporation, Kenilworth Verfahren für die enantioselektive synthese von azetidinon-zwischenprodukten
US20030137689A1 (en) * 2002-01-18 2003-07-24 General Instrument Corporation. Remote printer driver server
AU2003223627B2 (en) * 2002-04-18 2006-10-12 Schering Corporation (1-4-piperidinyl) benzimidazole derivatives useful as histamine H3 antagonists
US7220735B2 (en) 2002-04-18 2007-05-22 Schering Corporation Benzimidazolone histamine H3 antagonists
US7105505B2 (en) * 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
DE10227508A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227507A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227506A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
KR20050009757A (ko) 2002-06-24 2005-01-25 쉐링 코포레이션 히스타민 ｈ３ 길항제로서 유용한 인돌 유도체
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
CN1330667C (zh) 2002-08-06 2007-08-08 塞诺菲-安万特德国有限公司 分离肠胆固醇结合蛋白的方法
US20040198743A1 (en) * 2003-01-31 2004-10-07 Schering Corporation Methods for treating allergic skin and allergic ocular conditions using combinations of histamine receptor antagonists
US7235543B2 (en) * 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7208486B2 (en) * 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1606287B1 (de) * 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
GB0308333D0 (en) 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
PT1615909E (pt) 2003-04-23 2008-10-30 Glaxo Group Ltd Derivados de piperazina e a sua utilização para o tratamento de doenças neurológicas e psiquiátricas
US20040224952A1 (en) * 2003-05-07 2004-11-11 Cowart Marlon D. Fused bicyclic-substituted amines as histamine-3 receptor ligands
JP2005015434A (ja) 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
GB0315360D0 (en) 2003-07-01 2003-08-06 Burns Robert N Anti-theft device
WO2005009955A1 (en) 2003-07-31 2005-02-03 Hetero Drugs Limited Ezetimibe polymorphs
US20070072812A1 (en) 2003-08-25 2007-03-29 Microbia, Inc. Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
US20070161577A1 (en) 2003-08-28 2007-07-12 Martinez Eduardo J Tethered dimers and trimers of 1,4-diphenylazetidin-2-ones
GB0321228D0 (en) 2003-09-10 2003-10-08 Inpharmatica Ltd Modulating cell activity
AU2004275444A1 (en) 2003-09-26 2005-04-07 Forbes Medi-Tech Inc. Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers
EP1522541A1 (de) 2003-10-07 2005-04-13 Lipideon Biotechnology AG Neue hypocholesterolemische Verbindungen
EP1682117A1 (de) 2003-10-30 2006-07-26 Merck & Co., Inc. 2-azetidinone als anti-hypercholesterinämische mittel
WO2005042692A2 (en) 2003-10-31 2005-05-12 Forbes Medi-Tech Inc. A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
ATE428411T1 (de) 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
US7320972B2 (en) 2003-11-10 2008-01-22 Microbia, Inc. 4-Biarylyl-1-phenylazetidin-2-ones
GB0329778D0 (en) 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
ATE485267T1 (de) 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
WO2005062824A2 (en) 2003-12-23 2005-07-14 Merck & Co., Inc. Anti-hypercholesterolemic compounds

Also Published As

Publication number Publication date
AR054787A1 (es) 2007-07-18
JP2008546784A (ja) 2008-12-25
CN101243072A (zh) 2008-08-13
CA2610959A1 (en) 2007-01-04
HK1121737A1 (en) 2009-04-30
KR20080021082A (ko) 2008-03-06
ES2337727T3 (es) 2010-04-28
US20070015807A1 (en) 2007-01-18
EP1902046B1 (de) 2009-12-02
DE602006010870D1 (de) 2010-01-14
US7635705B2 (en) 2009-12-22
WO2007001975A1 (en) 2007-01-04
AU2006262441A1 (en) 2007-01-04
WO2007001975A8 (en) 2008-01-24
MX2008000115A (es) 2008-03-18
TW200738676A (en) 2007-10-16
US7846946B2 (en) 2010-12-07
US20090286830A1 (en) 2009-11-19
ZA200710968B (en) 2009-03-25
IL187984A0 (en) 2008-03-20
EP1902046A1 (de) 2008-03-26

Similar Documents

Publication Publication Date Title
ATE450526T1 (de) Als antagonisten von histamin h3 geeignete piperidinderivate
ATE344798T1 (de) Als histamin-h3-antagonisten geeignete indolderivate
ATE521607T1 (de) Piperidinderivate als renin-inhibitoren
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE452635T1 (de) Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE448217T1 (de) Substituierte piperidine als renin-inhibitoren
ATE461191T1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
ATE449091T1 (de) Substituierte triazolderivate als oxytocinantagonisten
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
DE602006008945D1 (de) Isochinolinderivate als inhibitoren von rho-kinase
DE602005014646D1 (de) Substituierte propenylpiperazinderivate als neue inhibitoren von histondeacetylase
ATE524467T1 (de) Neuartige aza-heterozyklen als kinase-inhibitoren
DE60319813D1 (de) 1-(4-piperidinyl)benzimidazole als histamin h3 antagonisten
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
ATE530545T1 (de) Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
ATE394391T1 (de) Indolderivate als histaminrezeptorantagonisten
ATE414698T1 (de) Durch 5gliedrige heterocyclen substituierte mtp- inhibierende arylpiperidine oder -piperazine
DE60320529D1 (de) Chinolinderivate als npy antagonisten
ATE509011T1 (de) Pyrimidinderivate als 11beta-hsd1-inhibitoren
DE602006019624D1 (de) Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
ATE427299T1 (de) Indol-2-carboxamidin-derivate als antagonisten der nmda-rezeptoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties